|
货号 | 品名 | 规格 | 包装 | 单价 | 货期 | 库存 |
JD200512101506 | Obinutuzumab | -- | 5mg | 16200元 | 咨询客服 | 3天 |
JD200512101456 | Obinutuzumab | -- | 1mg | 6600元 | 咨询客服 | 3天 |
性状: | Obinutuzumab (GA101) 是新型糖工程化II型CD20单克隆抗体,开发用来治疗非霍奇金淋巴瘤。 |
质量标准: | Description Obinutuzumab (GA101) a novel glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma. Shipping Shipping with dry ice. Storage Please store the product under the recommended conditions in the Certificate of Analysis. References [1]. Herter S, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013 Oct;12(10):2031-42. [2]. Dalle S, et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody -GA101. Mol Cancer Ther. 2011 Jan;10(1):178-85. [3]. Herting F, et al. Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab(GA101) in combination with chemotherapy in xenograft models of human lymphoma. Leuk Lymphoma. 2014 Sep;55(9):2151-5160. |